JPMorgan Chase & Co. Boosts Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $38.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price target lifted by JPMorgan Chase & Co. from $33.00 to $38.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 136.17% from the stock’s current price.

A number of other equities analysts also recently issued reports on the stock. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective on the stock. StockNews.com upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 15th. Stifel Nicolaus upped their price objective on shares of Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Bank of America lifted their target price on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, Citigroup upped their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $37.64.

Syndax Pharmaceuticals Price Performance

NASDAQ:SNDX opened at $16.09 on Thursday. Syndax Pharmaceuticals has a one year low of $15.00 and a one year high of $25.34. The company has a market cap of $1.37 billion, a PE ratio of -4.43 and a beta of 0.92. The firm has a 50-day moving average of $18.66 and a 200-day moving average of $20.05.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analysts’ expectations of $9.16 million. During the same period last year, the company earned ($0.73) earnings per share. On average, equities research analysts expect that Syndax Pharmaceuticals will post -3.69 earnings per share for the current fiscal year.

Institutional Trading of Syndax Pharmaceuticals

A number of large investors have recently bought and sold shares of SNDX. Iron Triangle Partners LP bought a new position in Syndax Pharmaceuticals during the first quarter worth about $23,159,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. bought a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter valued at $15,165,000. Eventide Asset Management LLC purchased a new stake in Syndax Pharmaceuticals during the 3rd quarter worth about $15,150,000. First Turn Management LLC bought a new position in Syndax Pharmaceuticals in the 2nd quarter worth about $13,147,000. Finally, Vanguard Group Inc. grew its holdings in Syndax Pharmaceuticals by 13.6% during the 1st quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock valued at $117,262,000 after buying an additional 591,631 shares in the last quarter.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).